Keywords: Pfizer, Theraclone, R&D, Licensing collaboration, Antibodies, Cancer, Infectious disease

Theraclone set to earn up to $632 million in antibodies deal with Pfizer

Article | 20 January 2011

Print This

Privately held, Seattle-based discovery-stage biotech firm Theraclone Sciences says it has entered into a multi-year R&D collaboration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in